4.540USDMkt Cap: 634.07M USDP/E: —Last update: 2026-05-21
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company produ…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap634.07M USD
Enterprise Value530.64M USD
Revenue (TTM)8.37M USD
Gross Profit542.00K USD
Net Income (TTM)-64.92M USD
Revenue/Share0.0670 USD
Last Price4.540 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees69
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.25
PEG—
EV/EBITDA-6.76
EV/Revenue63.42
P/S75.78
P/B4.41
EPS (TTM)-0.56
EPS (Forward)-0.73
52W Range
4.45069% of range4.580
52W High4.580 USD
52W Low4.450 USD
Profitability
Gross Margin6.93%
Oper. Margin-1111.82%
EBITDA Margin0.00%
Profit Margin-829.58%
ROE-62.98%
ROA-40.46%
Growth
Revenue Growth37.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-47.11M USD
CapEx (TTM)111.00K USD
FCF Margin-384.98%
FCF Yield-5.08%
Net Debt-103.43M USD
Net Debt/EBITDA1.32
Balance Sheet
Debt/Equity1.38
Current Ratio4.03
Quick Ratio4.03
Book Value/Sh1.029 USD
Cash/Share0.7550 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)9.667 USD
Target Range4.000 USD – 16.00 USD
# Analysts9
Ownership
Shares Out.139.66M
Float113.21M
Insiders2.23%
Institutions79.65%
Short Interest
Short Ratio5.5d
Short % Float6.46%
Short % Out.5.65%
Shares Short7.89M
Short (prev mo.)7.02M
Technical
SMA 504.159 (+9.2%)
SMA 2002.988 (+52.0%)
Beta0.78
S&P 52W Chg28.31%
Avg Vol (30d)460.49K
Avg Vol (10d)1.39M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—